CAR-T represents a major paradigm shift in cancer treatment. @biocom commends @CMSGov for proposing changes that ensure adequate payment for CAR-T which will reduce the burden on hospitals and expand patient access. See our 2021 #IPPS Comment Letter: https://t.co/rJ69SiJ4fq
BREAKING: @BiocomInstitute, @illumina, and Illumina Foundation Partner to Bring Genomics Education to the Classroom with Illumina Genomic Discoveries Program. More: https://t.co/uh9M1xwePL
BREAKING: Biocom Proudly Endorses California Proposition 14, the Stem Cell Research Institute Bond Initiative. Full details: https://t.co/aod9obmJun @CIRMnews
(1/2) Dr. James Smith, Deputy Director of Clinical Policy at the Office of New Drugs provided insight on @US_FDA’s Coronavirus Treatment Acceleration Program (CTAP).
He emphasized that although timelines have been shortened b/c of the very high priority placed on #COVID19
Cancer screenings have declined during #COVID19. Dr. Paul Kluetz, Deputy Director of the Oncology Center of Excellence, shared that @US_FDA is supportive of screening tests that could be performed in a less-invasive way.
In our webinar w/@US_FDA, Dr. Corrigan-Curay shared key considerations for ongoing or initiating clinical trials:
🦺 Safety is paramount
⚠️ #COVID19-related limitations pose safety risks to patients
👩⚕️ Investigator availability
💊 Availability of clinical trial staff & supplies
HAPPENING NOW: Dr. Jacqueline Corrigan-Curay updating our members on @US_FDA guidance on how to best conduct clinical trials during the #COVID19 pandemic.
We @biocom are very honored today to be hosting an important webinar on clinical trial in the area of COVID-19 with high-level insights from @US_FDA speakers. Below, Dr. Jaqueline Corrigan-Curay, Dir of the Office of Medical Policy presents to participants.
Last chance to register for tomorrow's webinar, in partnership with @US_FDA, on conducting clinical trials in the era of COVID-19!
https://t.co/5XpNmoIxmD
The challenges brought on by the COVID-19 pandemic have caused many life science companies to reconsider clinical trial timelines and operations. Learn how to overcome these challenges and others: https://t.co/cSlZSYifYt
In this week's @biocom Reimbursement Rundown: CMS proposes changes to docs' Medicare payments for 2021, including payment cuts for some specialties; 2021 OPPS proposed rule: CMS looks to eliminate inpatient-only list, increase 340B payment cuts. https://t.co/SOnY5IjSNK
In this week's @biocom Regulatory Rundown: #PDUFAVII: FDA, industry preview their reauthorization wish lists; FDA proposes reporting rule for Right to Try Act. https://t.co/tHf6cqAF8E
The FDA Emergency Use Authorization (EUA) process can be difficult to navigate, especially in an ever-evolving landscape. Learn how to best prepare for and submit EUAs in our upcoming webinar: https://t.co/yFHsVQeG2v
The challenges brought on by the COVID-19 pandemic have caused many life science companies to reconsider clinical trial timelines and operations. Learn how to overcome these challenges and others: https://t.co/cSlZSYifYt
Biocom and other leading state associations for life sciences submitted comments to @CMSGov re Medicaid rule on value-based agreements and patient assistance programs.
Read the full letter: https://t.co/cqETrVAxU5
@BioNJ_Org@CALifeSciences@HINJ_ORG@michbio@LifeSciencesPA
Throughout the #COVID19 pandemic and beyond, California's life science companies are driving scientific advancements that dramatically improve lives.
For 25 years, Biocom has been supporting this community of visionaries and risk-takers. Here's what that means to us.
According to Biocom’s 2020 Economic Impact Report, the number of jobs in biochemist and biophysicist occupations for San Diego County is 4.8x higher than the national average. See all wage and employment data: https://t.co/9btdfwX2qx